Cargando…

Effectiveness of Protease Inhibitor Monotherapy versus Combination Antiretroviral Maintenance Therapy: A Meta-Analysis

BACKGROUND: The unparalleled success of combination antiretroviral therapy (cART) is based on the combination of three drugs from two classes. There is insufficient evidence whether simplification to ritonavir boosted protease inhibitor (PI/r) monotherapy in virologically suppressed HIV-infected pat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mathis, Sandra, Khanlari, Bettina, Pulido, Federico, Schechter, Mauro, Negredo, Eugenia, Nelson, Mark, Vernazza, Pietro, Cahn, Pedro, Meynard, Jean-Luc, Arribas, Jose, Bucher, Heiner C.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2011
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139616/ https://www.ncbi.nlm.nih.gov/pubmed/21811554 http://dx.doi.org/10.1371/journal.pone.0022003

Ejemplares similares

Neurocognitive Impairment in Patients Treated with Protease Inhibitor Monotherapy or Triple Drug Antiretroviral Therapy
por: Pérez-Valero, Ignacio, et al.
Publicado: (2013)

Antiretroviral Simplification with Darunavir/Ritonavir Monotherapy in Routine Clinical Practice: Safety, Effectiveness, and Impact on Lipid Profile
por: Santos, José R., et al.
Publicado: (2012)

Dolutegravir Monotherapy as Maintenance Strategy: A Meta-Analysis of Individual Participant Data From Randomized Controlled Trials
por: Fournier, Anna L, et al.
Publicado: (2022)

Ritonavir-boosted protease inhibitor monotherapy is 6% less effective than combination antiretroviral therapy in a meta-analysis
por: Bierman, WFW, et al.
Publicado: (2010)

Boosted protease inhibitor monotherapy in HIV-infected adults: outputs from a pan-European expert panel meeting
por: Arribas, José R, et al.
Publicado: (2013)

No Differences of Immune Activation and Microbial Translocation Among HIV-infected Children Receiving Combined Antiretroviral Therapy or Protease Inhibitor Monotherapy
por: Falcon-Neyra, Lola, et al.
Publicado: (2015)

Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM)
por: Garay, Osvaldo Ulises, et al.
Publicado: (2019)

The state of PI monotherapy and NRTI-sparing therapy
por: Arribas, JR
Publicado: (2010)

Prioritization of antiretroviral therapy in patients with high CD4 counts, and retention in care: lessons from the START and Temprano trials
por: Schechter, Mauro
Publicado: (2018)

Next generation sequencing of HIV-1 protease in the PIVOT trial of protease inhibitor monotherapy
por: Dunn, David T., et al.
Publicado: (2018)

Analysis of major and minor IAS-USA PI mutations in the MONET trial of darunavir/ritonavir monotherapy versus DRV/r + 2NRTIs
por: Pulido, F, et al.
Publicado: (2010)

Inflammatory, procoagulant markers and HIV residual viremia in patients receiving protease inhibitor monotherapy or triple drug therapy: a cross-sectional study
por: Estébanez, Miriam, et al.
Publicado: (2014)

The burden of chronic obstructive pulmonary disease associated with maintenance monotherapy in the UK
por: Edwards, Susan C, et al.
Publicado: (2016)

Stable HIV‐1 reservoirs on dolutegravir maintenance monotherapy: the MONODO study
por: Sculier, D, et al.
Publicado: (2018)

554. Does Protease Inhibitor (PI) Monotherapy Select Primary PI Resistance?
por: Saling, Christopher, et al.
Publicado: (2018)

Maintenance ramucirumab monotherapy after intolerable toxicities following docetaxel plus ramucirumab
por: Hata, Akito, et al.
Publicado: (2018)

Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa
por: Sutherland, Katherine A., et al.
Publicado: (2015)

Effectiveness of Ritonavir-Boosted Protease Inhibitor Monotherapy in Clinical Practice Even with Previous Virological Failures to Protease Inhibitor-Based Regimens
por: López-Cortés, Luis F., et al.
Publicado: (2016)

Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial
por: Sutherland, Katherine A., et al.
Publicado: (2015)

HIV-1 subtype influences susceptibility and response to monotherapy with the protease inhibitor lopinavir/ritonavir
por: Sutherland, K. A., et al.
Publicado: (2015)

Correction: Evidence for Reduced Drug Susceptibility without Emergence of Major Protease Mutations following Protease Inhibitor Monotherapy Failure in the SARA Trial
por: Sutherland, Katherine A., et al.
Publicado: (2016)

Predictors of virological failure in HIV‐1‐infected patients switching to dolutegravir maintenance monotherapy
por: Wijting, IEA, et al.
Publicado: (2018)

TNF-α inhibitors used as steroid-sparing maintenance monotherapy in parenchymal CNS sarcoidosis
por: Hilezian, Frédéric, et al.
Publicado: (2021)

Nevirapine and Efavirenz Elicit Different Changes in Lipid Profiles in Antiretroviral- Therapy-Naive Patients Infected with HIV-1
por: van Leth, Frank, et al.
Publicado: (2004)

Protease inhibitor monotherapy is associated with a higher level of monocyte activation, bacterial translocation and inflammation
por: Torres, Berta, et al.
Publicado: (2014)

A randomized pilot trial to evaluate the benefit of the concomitant use of atorvastatin and Raltegravir on immunological markers in protease-inhibitor-treated subjects living with HIV
por: Negredo, Eugènia, et al.
Publicado: (2020)

Antiretroviral therapy suppressed participants with low CD4(+) T-cell counts segregate according to opposite immunological phenotypes
por: Pérez-Santiago, Josué, et al.
Publicado: (2016)

Impact of HIV-1 Subtype and Antiretroviral Therapy on Protease and Reverse Transcriptase Genotype: Results of a Global Collaboration
por: Kantor, Rami, et al.
Publicado: (2005)

Immunological predictors of CD4(+ )T cell decline in antiretroviral treatment interruptions
por: Seoane, Elena, et al.
Publicado: (2008)

Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in rural health facilities in southern Cameroon
por: Sayang, Collins, et al.
Publicado: (2009)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA
por: Wandeler, Gilles, et al.
Publicado: (2011)

Effects of HIV-1 protease on cellular functions and their potential applications in antiretroviral therapy
por: Yang, Hailiu, et al.
Publicado: (2012)

Predictors of failure on second-line antiretroviral therapy with protease inhibitor mutations in Uganda
por: Musana, Hellen, et al.
Publicado: (2021)

Management of Antiretroviral Therapy with Boosted Protease Inhibitors—Darunavir/Ritonavir or Darunavir/Cobicistat
por: Marin, Ruxandra-Cristina, et al.
Publicado: (2021)

Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in urban health facilities in Yaoundé, central province, Cameroon
por: Sayang, Collins, et al.
Publicado: (2009)

Virological findings from the SARA trial: boosted PI monotherapy as maintenance second-line ART in Africa
por: Pillay, D, et al.
Publicado: (2010)

Long-Term Maintenance of Certolizumab Pegol Safety and Efficacy, in Combination with Methotrexate and as Monotherapy, in Rheumatoid Arthritis Patients
por: Fleischmann, Roy, et al.
Publicado: (2017)

Biologic monotherapy versus combination therapy with immunomodulators in the induction and maintenance of remission of Crohn’s disease and ulcerative colitis
por: Hashash, Jana G., et al.
Publicado: (2021)

Maintenance darunavir/ritonavir monotherapy to prevent perinatal HIV transmission, ANRS-MIE 168 MONOGEST study
por: Mandelbrot, Laurent, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_gnn4p3lj4q1n05vgg6cfrtb2nu